ChondroGene gets TSX listing, changes name to GeneNews

By Elaine Rigoli

Tampa, Fla., Sept. 22 - ChondroGene, Ltd. received conditional approval to list its common shares on the Toronto Stock Exchange subject to filing of final documentation.

It is expected that the company's common shares will start trading on the exchange by Oct. 31, according to a company news release.

Further, the Toronto-based biopharmaceutical company will change its name to GeneNews, Ltd. and will trade under the symbol GEN.

ChondroGene said it received shareholder approval to change its name at the last annual meeting held on June 12. In conjunction with its move to the Toronto Stock Exchange, ChondroGene common shares will be delisted from and cease trading on the TSX Venture Exchange.

"Listing on the TSX is a significant achievement for our company and a natural progression in our growth. At the same time we will be changing our name to GeneNews, Ltd. since we have broadened our focus beyond osteoarthritis and have applied our Sentinel Principle technology to many disease areas. GeneNews more accurately reflects the business of the company in taking a genomics approach to the study of all disease and the development of disease-specific tests such as ColonSentry, our first commercial product," president and chief executive officer K. Wayne Marshall said in the release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.